

Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_71110
Title of the Manuscript:	Case Report on Management and Outcomes of COVID-19 in a Patient with Cirrhosis of Liver
Type of the Article	Case Report

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

<http://peerreviewcentral.com/page/manuscript-withdrawal-policy>

Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	<p>The symptom of Breathlessness was quoted to be present for past 3 months associated with distension of abdomen in the case history, on what grounds the diagnosis of Covid-19 was suspected and how was it diagnosed? Was it diagnosed by RT-PCR/TrueNat/RAT/GeneXpert? Breathlessness of 3 months duration in this case seems to be due to volume overload due to cirrhosis of liver. What were the clinical symptoms of Covid-19 present in your case? Was there a history of fever / body ache/ sore throat/ loose stools/ worsening of breathlessness...</p> <p>Manuscript mentions that the patient had covid-19 pneumonia, how was pneumonia diagnosed? Was CT chest or Chest X ray done? If yes then mention the severity of lesion as well as enclose the images.</p> <p>What was the indication for Inj Remdesivir? What was the patients Spo2 at which Remdesivir was started? Manuscript says that Spo2 monitoring was done, but no further details on the lowest Spo2 recorded is mentioned and the need for Oxygen or assisted ventilation is not mentioned in the manuscript</p> <p>Also the titres of AST and ALT are not mentioned in the manuscript, the levels of these 2 enzymes are very crucial in determining contraindication for Remdesivir use. The dose of Remdesivir used in this patient has to be clearly mentioned along with the duration of use.</p> <p>Enumerate the justification for using Interferon alpha 2b in your case, what was the dose and route of administration? Justify its use in a patient who has normal saturation in room air. Since her saturation was normal in room air, did the patient recover on her own or due to interferon alpha 2b or due to Remdesivir / albumin administration?</p> <p>What was the patient's Total protein and Serum Albumin level? Was any diuretics / therapeutic paracentesis done on this patient?</p> <p>What was the dose of Prednisolone used and why was it administered twice a day? And for how long was the drug administered?</p> <p>There is also a mention on Immunoglobulin in the manuscript? But no further details are included in the write up, it would be better if further details are added up in the manuscript.</p>	
Minor REVISION comments	The Brand names of multiple drugs like Syp Duphalac, Proteinex, Momate-T cream and Rifagut are used, it is recommended to use pharmacologic / generic names and full dose and route of administration.	
Optional/General comments		

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

Review Form 1.6

As per the guideline of editorial office we have followed VANCOUVER reference style for our paper.

Kindly see the following link:

<http://sciencedomain.org/archives/20>

Reviewer Details:

Name:	S. Lokesh
Department, University & Country	ICMR-National Institute of Epidemiology, India